NEW YORK, NY -- (Marketwire) -- 07/10/12 -- OTCEquity, the leader for breaking information and up-to-date market activities in North America's speculative markets, locates high-growth equity opportunities or equities with unrealized value to keep investors one step ahead of the crowd. OTCEquity offers market research and exclusive reports on specific stand-out situations as they demand attention. Today OTCEquity issued a breaking report: "Speculative Biotech: Four Small Biotechs You Should Know," including Keryx Biopharmaceuticals (NASDAQ: KERX), Geron Corp. (NASDAQ: GERN), Cell Therapeutics (NASDAQ: CTIC), and OncoSec Medical Inc (OTCBB: ONCS).
Keryx Biopharmaceuticals (NASDAQ: KERX) has a market cap of $143 million with $30.91 million in cash on the Company's books. Keryx's states in their "About Us" that they are "focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease." Their recent advancements have also put them on the other end of speculative acquisition talk of late, which could be one of several causes for recent activity.
Other causes could include the short-term chart, low debt, indicators, and more. Find out where KERX is moving and why, read the free breaking report here: www.otcequity.com/exclusive.php?post=2316
Geron Corp. (NASDAQ: GERN) is still well off of its 52-week high of 4.39; however, it has risen 32% in the past month since hitting a 52-week low on June 7, 2012. Geron is a biopharmaceutical company developing first-in-class therapies for cancer.
Find out where GERN is moving and why, read the free breaking report here: www.otcequity.com/exclusive.php?post=2316
Cell Therapeutics (NASDAQ: CTIC) has a market cap of more than $122 million, although at 0.60 it is flirting with the stock's 52-week low of 0.56 and is currently 63% off of the 52-week high of 1.65. The Company is currently focused on efforts to reduce spending by re-prioritizing its portfolio. CTIC is committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable.
CTIC is focused on the launch of Pixuvri® in the EU; however, some investors point out the Company's debt to cash ratio of 0% is a potential propellant to turn the downward movement back in a positive direction.
Find out where CTIC is moving and why, read the free breaking report here: www.otcequity.com/exclusive.php?post=2316
OncoSec Medical Inc (OTCBB: ONCS) released news Monday, announcing that the Company initiated its Phase II Clinical Program in Cutaneous T-Cell Lymphoma. The announcement sent shares higher for the second straight session and ignited the imagination of investors. ONCS closed Monday at 0.27 with a market cap just north of $15 million.
Like KERX, short-tem indicators and the chart are attracting attention for ONCS. The question is: "When does imagination conflict with speculation?" What are the prospects if it doesn't? Find out where ONCS is moving and why, read the free breaking report here: www.otcequity.com/exclusive.php?post=2316
This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Information, opinions and analysis contained herein are based on sources deemed to be reliable and are subject to change without notice. A third party has hired and paid IO NewsWire one thousand two hundred and ninety five dollars for the publication and circulation of this news release. Accordingly, certain information included herein may be forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. However, no representation, expressed or implied, is made as to the accuracy, completeness or correctness. In light of the above, we accept no liability for any losses arising from an investor's reliance on or use of this report. We do not and have not had any ownership interest in said third party of any kind.